+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Encephalopathy Drug"

Hepatic Encephalopathy Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Hepatic Encephalopathy Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • June 2020
  • 144 Pages
  • Global
From
From
Hepatic Encephalopathy - Pipeline Review, H2 2020 - Product Thumbnail Image

Hepatic Encephalopathy - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 96 Pages
  • Global
From
Encephalopathy - Pipeline Review, H1 2020 - Product Thumbnail Image

Encephalopathy - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 81 Pages
  • Global
From
From
Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018 - Product Thumbnail Image

Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018

  • Drug Pipelines
  • August 2018
  • 30 Pages
  • Global
From
From
From
Loading Indicator

The Encephalopathy Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat diseases and disorders of the brain and spinal cord. Encephalopathy drugs are used to treat a variety of conditions, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. These drugs are typically administered orally, intravenously, or intramuscularly, depending on the severity of the condition. Commonly used encephalopathy drugs include acetylcholinesterase inhibitors, anticonvulsants, and anti-inflammatory agents. Some of the major companies in the Encephalopathy Drug market include Pfizer, Merck, Novartis, GlaxoSmithKline, and Sanofi. Other companies include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Johnson & Johnson. Show Less Read more